EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain

J F Silvestre-Salvador, S Santos-Alarcón, A Mengual-Sendra, V Zaragoza-Ninet, M P Ortega-García, M Rodriguez, E Monte-Boquet, R F Ruiz de Apodaca, N Pérez Prior, F J Miquel-Miquel, J Borras-Blasco

Actas Dermo-Sifiliográficas · 2026

DOI: 10.1016/j.ad.2025.104563 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Actas Dermo-Sifiliográficas, 2026. Verfasst von J F Silvestre-Salvador und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, General University Hospital Dr. Balmis, ISABIAL, Alicante, Spain. Electronic address: silvestre.jfr@gmail.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Sanofi Aventis SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The safety and efficacy profile of dupilumab in the management of atopic dermatitis (AD) are established in clinical trials. However, long-term real-world persistence data in Spain are limited. OBJECTIVE: The primary endpoint of the study was to assess the 4-year persistence of dupilumab in routine clinical practice in patients with moderate-to-severe AD. Secondary endpoints included the analysis of safety and efficacy profile during the same period of time. METHODS: We conducted a retrospective cohort study of dispensation registries and health records from 5 hospitals. Adults with moderate-to-severe AD starting on dupilumab treatment were followed for 4-years. Dupilumab persistence was estimated using Kaplan-Meier analysis. Efficacy was measured by changes in EASI and IGA scores. Significant adverse events (AEs) leading to discontinuation were recorded. RESULTS: A total of 251 patients included (mean age, 46 years; 59.4%, men; 64.5% with at least 1 atopic comorbidity; mean time from AD diagnosis, 14.5 years). Of these, 196 (78.1%) had been on ≥2 systemic therapies before starting dupilumab. Baseline EASI and IGA values averaged 27.9 and 4.0, respectively. Persistence rates were 90%, 80%, 78%, and 73% after 1, 2, 3, and 4-years, respectively. By 16 weeks, 47.8% and 54.7% of patients achieved EASI ≤3 or IGA ≤1, increasing to 76.3% and 77.2% by 52 weeks, and reaching 90.9% in the group followed for >3 years. A total of 38 patients (13.5%) discontinued dupilumab, mainly due to inefficacy (5.6%) and AEs (1.2%). CONCLUSION: Dupilumab effectively reduced AD severity within the first few weeks, with most patients achieving mild/minimal disease activity or complete clearance by year 1. The observed safety profile was consistent with known data. High persistence rates up to 4-years suggest satisfaction with dupilumab long-term safety and efficacy profile in managing moderate-to-severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesMaleFemaleSpainMiddle AgedAdultTreatment OutcomeTime Factors

Stichwörter der Autor:innen

Atopic dermatitisDupilumabEfficacyLong-term treatmentPersistenceReal-lifeSafety

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Department, General University Hospital Dr. Balmis, ISABIAL, Alicante, Spain. Electronic address: silvestre.jfr@gmail.com.
  • Dermatology Department, Virgen de los Lirios Hospital, Alcoi, Spain.
  • Hospital Farmacy Department, Arnau de Vilanova Hospital, Valencia, Spain.
  • Dermatology Department, Consortium General University Hospital of Valencia, Valencia, Spain.
  • Dermatology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
  • Dermatology Department, General University Hospital Dr. Balmis, ISABIAL, Alicante, Spain.

Förderung

  • Sanofi
  • Sanofi Aventis SA

Zitieren

APA

Silvestre-Salvador, J. F., Santos-Alarcón, S., Mengual-Sendra, A., Zaragoza-Ninet, V., Ortega-García, M. P., Rodriguez, M., Monte-Boquet, E., Ruiz de Apodaca, R. F., Pérez Prior, N., Miquel-Miquel, F. J., & Borras-Blasco, J. (2026). Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2025.104563

Vancouver

Silvestre-Salvador JF, Santos-Alarcón S, Mengual-Sendra A, Zaragoza-Ninet V, Ortega-García MP, Rodriguez M, et al. Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain. Actas Dermo-Sifiliográficas. 2026. doi:10.1016/j.ad.2025.104563

BibTeX
@article{SilvestreSalvador2026,
  author = {Silvestre-Salvador, J F and Santos-Alarcón, S and Mengual-Sendra, A and Zaragoza-Ninet, V and Ortega-García, M P and Rodriguez, M and Monte-Boquet, E and Ruiz de Apodaca, R F and Pérez Prior, N and Miquel-Miquel, F J and Borras-Blasco, J},
  title = {Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2026},
  doi = {10.1016/j.ad.2025.104563}
}
Kostenlos starten →